A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Inclusion Criteria

• •Subjects with advanced and/or metastatic solid tumors who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist.
• •ECOG performance status ≤ 2
• •Accessible for treatment, PK sample collection and required study follow-up
• •Total Bilirubin ≤ 1.5 x ULN and ALT, AST ≤ 2.5 x ULN